...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents.
【24h】

Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents.

机译:多取代的吡唑,第5部分。新的1-(4-氯苯基)-4-羟基-1H-吡唑-3-羧酸酰肼类似物和一些衍生的环系统的合成。一类潜在的抗肿瘤和抗HCV药物。

获取原文
获取原文并翻译 | 示例
           

摘要

A novel series of 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived 4-substituted-1,2,4-triazolin-3-thiones, 2-substituted-1,3,4-thiadiazole and 2-substituted-1,3,4-oxadiazoles has been synthesized. Ten of the newly synthesized compounds were selected by the National Cancer Institute (NCI)-in vitro-disease oriented antitumor screening to be evaluated for their antitumor activity. Seven compounds, namely 7a-c, 9, 11, 13 and 14, exhibited potential and broad spectrum antitumor activity against most of the tested subpanel tumour cell lines (GI50<100 microM). Compounds 14 (GI50, TGI, and LC50 MG-MID values of 0.08, 15.8 and 64.6 microM, respectively) and 11 (GI50, TGI, and LC50 MG-MID values of 0.20, 11.7 and 87.1 microM, respectively) proved to be the most active members in this study with potential activity against all the tested subpanel tumour cell lines and particular effectiveness on the leukaemia subpanel at both the GI50 (0.03 and 0.09 microM, respectively) and the TGI levels (35.2 and 28.1 microM, respectively). Moreover, compound 14 exhibited a super sensitivity profile towards about 26 different cancer cell lines with GI50 values lying in the nanomolar concentration range (GI50 values<0.01 microM). In addition, compounds 2-5, 6a-d, 7a, 8-11, 12a, 13, 14 were investigated for their in vitro effect on the replication of hepatitis-C virus (HCV) in HepG2 hepatocellular carcinoma cell line infected with the virus using the reverse transcription-polymerase chain reaction (RT-PCR) technique. The results revealed that compounds 2 and 5 were capable of inhibiting the replication of both the HCV RNA (+) and (-) strands at 10-100 microg mL(-1) concentration range.
机译:一类新的1-(4-氯苯基)-4-羟基-1H-吡唑-3-羧酸酰肼类似物和一些衍生的4-取代-1,2,4-三唑啉-3-硫酮,2-取代-1已经合成了3,4-噻二唑和2-取代的1,3,4-恶二唑。美国国家癌症研究所(NCI)筛选了十种新合成的化合物,进行了体外疾病定向的抗肿瘤筛选,以评估其抗肿瘤活性。七种化合物,即7a-c,9、11、13和14,对大多数受测亚组肿瘤细胞系(GI50 <100 microM)表现出潜在的和广谱的抗肿瘤活性。化合物14(GI50,TGI和LC50 MG-MID值分别为0.08、15.8和64.6 microM)和11(GI50,TGI和LC50 MG-MID值分别为0.20、11.7和87.1 microM)被证明是这项研究中最活跃的成员,在GI50(分别为0.03和0.09 microM)和TGI水平(分别为35.2和28.1 microM)下,均具有针对所有测试的亚肿瘤细胞系的潜在活性,并且对白血病亚细胞特别有效。此外,化合物14对约26种不同的癌细胞系表现出超敏特性,其GI50值在纳摩尔浓度范围内(GI50值<0.01 microM)。此外,还研究了化合物2-5、6a-d,7a,8-11、12a,13、14在体外对感染了HepG2的HepG2肝癌细胞株中丙型肝炎病毒(HCV)复制的影响。病毒使用逆转录聚合酶链反应(RT-PCR)技术。结果表明,化合物2和5能够在10-100 microg mL(-1)浓度范围内抑制HCV RNA(+)和(-)链的复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号